HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, S. C. Articles by Reivich, M. Search for Related Content PubMed PubMed Citation Articles by Jones, S. C. Articles by Reivich, M.

The Radiation Dosimetry of 2-[F-18]Fluoro-2-Deoxy-D-Glucose in Man

University of Pennsylvania, Philadelphia, Pennsylvania
Brookhaven National Laboratory, Upton, New York

Correspondence: For reprints contact: Stephen C. Jones, PhD, Cerebrovascular Research Center, Rm. 429 Johnson Pavilion, 36th and Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104.

ABSTRACT

Bladder and brain time-activity measurements in humans were performed after the intravenous administration of 2-[F-18]fluoro-2-deoxy-D-glucose. Radiation doses were calculated using the MIRD schema. The bladder wall received an average of 440 mrad/mCi (s.e. 76) in ten subjects who voided at 2 hr after administration of tracer. If these subjects had voided at 1 hr, the bladder-wall dose would have been reduced to 220 mrad/mCi. The brain received an average of 81 mrad/mCi in eight subjects. The doses to other organs, calculated from published dog biodistribution data, are between 50 and 85 mrad/mCi except for spleen and heart, which both received 160 mrad/mCi. These time-activity measurements for the critical organ In the human avoid the assumptions made in using animal biodistribution data for human dosimetry calculations.

This article has been cited by other articles:

				M. G. Stabin Radiopharmaceuticals for Nuclear Cardiology: Radiation Dosimetry, Uncertainties, and Risk J. Nucl. Med., September 1, 2008; 49(9): 1555 - 1563. [Abstract] [Full Text] [PDF]

				P. B. Zanzonico, R. Finn, K. S. Pentlow, Y. Erdi, B. Beattie, T. Akhurst, O. Squire, M. Morris, H. Scher, T. McCarthy, et al. PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer J. Nucl. Med., November 1, 2004; 45(11): 1966 - 1971. [Abstract] [Full Text] [PDF]

				W. Robeson, V. Dhawan, A. Belakhlef, Y. Ma, V. Pillai, T. Chaly, C. Margouleff, D. Bjelke, and D. Eidelberg Dosimetry of the Dopamine Transporter Radioligand 18F-FPCIT in Human Subjects J. Nucl. Med., June 1, 2003; 44(6): 961 - 966. [Abstract] [Full Text] [PDF]

				M. T. Hays, E. E. Watson, S. R. Thomas, and M. Stabin MIRD Dose Estimate Report No. 19: Radiation Absorbed Dose Estimates from 18F-FDG J. Nucl. Med., February 1, 2002; 43(2): 210 - 214. [Full Text] [PDF]

				T. Higashi, S. J. Fisher, R. S. Brown, K. Nakada, G. L. Walter, and R. L. Wahl Evaluation of the Early Effect of Local Irradiation on Normal Rodent Bone Marrow Metabolism Using FDG: Preclinical PET Studies J. Nucl. Med., December 1, 2000; 41(12): 2026 - 2035. [Abstract] [Full Text] [PDF]

				P. D. Shreve, Y. Anzai, and R. L. Wahl Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants RadioGraphics, January 1, 1999; 19(1): 61 - 77. [Abstract] [Full Text] [PDF]